TYK2 in Immune Responses and Treatment of Psoriasis

被引:13
|
作者
Shang, Lin [1 ]
Cao, Jiali [1 ]
Zhao, Siqi [1 ]
Zhang, Jingya [1 ]
He, Yanling [1 ]
机构
[1] Capital Med Univ, Affiliated Beijing Chaoyang Hosp, Dept Dermatol, Beijing, Peoples R China
关键词
TYK2; psoriasis; Janus kinase-signal transducer and activator of transcription; autoimmunity; inhibition; TYROSINE KINASE 2; PLAQUE PSORIASIS; CYTOKINE RESPONSES; PARTIAL IMPAIRMENT; DENDRITIC CELLS; SIGNALING AXIS; DOUBLE-BLIND; IL-23; SAFETY; INHIBITOR;
D O I
10.2147/JIR.S380686
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tyrosine kinase 2 (TYK2), a key part of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, plays an integral role in the differentiation and immune responses of intrinsic immune cells and regulates the mediation of cytokines. TYK2 leads to inflammatory cascade responses in the pathogenesis of immune-mediated inflammatory diseases (IMIDs), especially psoriasis. Small-molecule TYK2 inhibitors are considered to be an effective strategy for modulating psoriasis. Here, we attempt to review the pro-inflammatory mechanisms of the JAK-STAT signaling pathway, the regulatory roles of TYK2 in the pathogenesis of psoriasis, and provide updates on ongoing and recently completed trials of TYK2 inhibitors.
引用
收藏
页码:5373 / 5385
页数:13
相关论文
共 50 条
  • [1] TYK2 inhibition: changing the treatment landscape for psoriasis?
    Abduelmula, Abrahim
    Gooderham, Melinda J.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (03) : 185 - 187
  • [2] JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
    Miguel Nogueira
    Luis Puig
    Tiago Torres
    Drugs, 2020, 80 : 341 - 352
  • [3] TYK2 as a novel therapeutic target in psoriasis
    Elyoussfi, Sarah
    Rane, Shraddha S.
    Eyre, Steve
    Warren, Richard B.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (06) : 549 - 558
  • [4] JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
    Nogueira, Miguel
    Puig, Luis
    Torres, Tiago
    DRUGS, 2020, 80 (04) : 341 - 352
  • [5] Successful treatment of nail psoriasis by switching to a TYK2 inhibitor after cyclosporine
    Kan, Yuji
    Horimoto, Kouhei
    Uhara, Hisashi
    JOURNAL OF DERMATOLOGY, 2025, 52 (02): : e180 - e181
  • [6] TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases
    Ghoreschi, Kamran
    Augustin, Matthias
    Baraliakos, Xenofon
    Kroenke, Gerhard
    Schneider, Matthias
    Schreiber, Stefan
    Schulze-Koops, Hendrik
    Zeissig, Sebastian
    Thaci, Diamant
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 (10): : 1409 - 1420
  • [7] Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis
    Kircik, Leon
    Aldredge, Lakshi M.
    DiRuggiero, Douglas
    JOURNAL OF DRUGS IN DERMATOLOGY, 2024, 23 (08) : 645 - 652
  • [8] Central TYK2 Inhibition Identifies TYK2 as a Key Neuroimmune Modulator
    Molitor, Tyler
    Hayashi, Genki
    Lin, Mei-Yao
    Dunn, Carissa
    Peterson, Nathan
    Poston, Robert
    Kurnellas, Michael
    Traver, David
    Patel, Seona
    Akgungor, Zeynep
    Leonardi, Virginia
    Lewis, Colizel
    Segales, Joshua
    Wood, Steve
    Rassoulpour, Arash
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 611 - 611
  • [9] Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
    Roskoski, Robert
    PHARMACOLOGICAL RESEARCH, 2023, 189
  • [10] Tyk2 is a therapeutic target for psoriasis-like skin inflammation
    Ishizaki, Masayuki
    Muromoto, Ryuta
    Akimoto, Toshihiko
    Sekine, Yuichi
    Kon, Shigeyuki
    Diwan, Manish
    Maeda, Hiroaki
    Togi, Sumihito
    Shimoda, Kazuya
    Oritani, Kenji
    Matsuda, Tadashi
    INTERNATIONAL IMMUNOLOGY, 2014, 26 (05) : 257 - 267